NuVasive (NUVA) Gets a Hold Rating from BTIG
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on NuVasive (NUVA). The company’s shares closed last Wednesday at $70.16, close to its 52-week high of $72.61.
According to TipRanks.com, Zimmerman is a top 100 analyst with an average return of 36.9% and a 63.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Zimmer Biomet Holdings.
Currently, the analyst consensus on NuVasive is a Moderate Buy with an average price target of $74.50, a 5.6% upside from current levels. In a report issued on May 2, Canaccord Genuity also maintained a Hold rating on the stock with a $66.00 price target.
See today’s analyst top recommended stocks >>
Based on NuVasive’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $292 million and net profit of $1.69 million. In comparison, last year the company earned revenue of $310 million and had a net profit of $29.88 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.
Read More on NUVA: